The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%

被引：0
|
作者：
Liebl, A.
Prager, R.
Kaiser, M.
Binz, K.
Gailwitz, B.
机构：
[1] Ctr Diabet & Metabol, Dept Diabet, Bad Heilbrunn, Germany
[2] L Boltzmann Res Inst Metab Dis & Nutr, Dept Diabet, Vienna, Austria
[3] Novo Nordisk Pharm GmbH, Mainz, Germany
[4] Triemli City Hosp, Dept Diabet, Zurich, Switzerland
[5] Univ Tubingen, Dept Diabet, Tubingen, Germany
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0998
引用
收藏
页码：610 / 611
页数：2
相关论文
共 50 条
  • [21] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
  • [22] A basal-bolus regimen of insulin glargine and insulin glulisine results in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-daily premixed insulin in type 2 diabetes patients
    Fritsche, A.
    Larbig, M.
    Haering, H. -U.
    DIABETOLOGIA, 2010, 53
  • [23] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    DIABETOLOGIA, 2011, 54 : S427 - S427
  • [24] Effects of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea
    Nauck, M. A.
    Duran, S.
    Kim, D.
    Johns, D.
    Festa, A.
    Trautmann, M.
    DIABETOLOGIA, 2006, 49 : 3 - 3
  • [25] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [26] Patients with type 2 diabetes not achieving glycemic targets on OADs with/without basal insulin can reach HbA1c targets with biphasic insulin aspart 30/70
    Jain, R
    Braceras, R
    Wahl, T
    Wahlen, J
    Bressler, P
    Deng, L
    Garber, A
    DIABETOLOGIA, 2005, 48 : A304 - A304
  • [27] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
    Palmer, AJ
    Roze, S
    Valentine, WJ
    Schmidt, I
    Wittrup-Jensen, KW
    DIABETES, 2004, 53 : A288 - A288
  • [28] Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type-2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification Experts Commentary
    Wascher, Thomas
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2015, 8 (03): : 88 - 88
  • [29] Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
    Kann, P. H.
    Wascher, T.
    Zackova, V.
    Moeller, J.
    Medding, J.
    Szocs, A.
    Mokan, M.
    Mrevlje, F.
    Regulski, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (09) : 527 - 532
  • [30] Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes
    Franek, E.
    Haluzik, M.
    Varzic, S. Canecki
    Sargin, M.
    Macura, S.
    Zacho, J.
    Christiansen, J. S.
    DIABETIC MEDICINE, 2016, 33 (04) : 497 - 505
12345